MeiraGTx Holdings PLC (NAS:MGTX)

$ 5.68 0.15 (2.71%) Market Cap: 365.26 Mil Enterprise Value: 324.79 Mil PE Ratio: 0 PB Ratio: 2.92 GF Score: 53/100

MeiraGTx Holdings PLC AAV-hAQP1 Clinical Program Update Call Transcript
Jun 27, 2023
MeiraGTx Holdings PLC at Bank of America Global Healthcare Conference Transcript
May 10, 2023
MeiraGTx Holdings PLC at Chardan Genetic Medicines & Cell Therapy Manufacturing Summit (Virtual) Transcript
Apr 24, 2023
MeiraGTx Holdings PLC to Present AAV-hAQP1 Phase 1 AQUAx Transcript
Dec 13, 2022
MeiraGTx Holdings PLC at Bank of America Biotech SMID Cap Conference Transcript
Dec 07, 2022
MeiraGTx Holdings PLC at Morgan Stanley Global Healthcare Conference Transcript
Sep 14, 2022
MeiraGTx Holdings PLC to Discuss Top-Line Data from the MGT009 Phase 1/2 Clinical Study of Botaretigene Sparoparvovec (AAV-RPGR) Transcript
Jun 28, 2022
MeiraGTx Holdings PLC at Bank of America Healthcare Conference Transcript
May 10, 2022
MeiraGTx Holdings PLC R&D Day (Virtual) Transcript
Dec 15, 2021
MeiraGTx Holdings PLC Xerostomia Clinical Program Update Call Transcript
Dec 07, 2021
MeiraGTx Holdings PLC at Barclays Gene Editing & Gene Therapy Summit (Virtual) Transcript
Nov 15, 2021
MeiraGTx Holdings PLC at Chardan Genetic Medicines Conference (Virtual) Transcript
Oct 05, 2021
MeiraGTx Holdings PLC Annual Shareholders Meeting Transcript
Jun 10, 2021
MeiraGTx Holdings PLC at Bank of America Global Research Healthcare Conference (Virtual) Transcript
May 12, 2021
MeiraGTx Holdings PLC at Barclays Global Healthcare Conference (Virtual) Transcript
Mar 11, 2021
MeiraGTx Holdings plc - Special Call Transcript
Dec 17, 2020
MeiraGTx Holdings PLC at Barclays Virtual Gene Editing & Gene Therapy Summit Transcript
Nov 16, 2020
MeiraGTx Holdings plc - Special Call Transcript
Jul 17, 2020
MeiraGTx Holdings PLC Annual Shareholders Meeting Transcript
Jun 02, 2020
MeiraGTx Holdings PLC at Bank of America Merrill Lynch Healthcare Conference (Virtual) Transcript
May 12, 2020
MeiraGTx Holdings PLC at Barclays Global Healthcare Conference Transcript
Mar 12, 2020
MeiraGTx Holdings plc - Special Call Transcript
Dec 13, 2019
MeiraGTx Holdings PLC AAO 2019 Call Transcript
Oct 13, 2019
MeiraGTx Holdings PLC at Bank of America Merrill Lynch Health Care Conference Transcript
May 15, 2019
MeiraGTx Holdings PLC at Barclays Global Healthcare Conference Transcript
Mar 12, 2019

MeiraGTx Holdings PLC to Discuss Top-Line Data from the MGT009 Phase 1/2 Clinical Study of Botaretigene Sparoparvovec (AAV-RPGR) Transcript

Jun 28, 2022 / 12:00PM GMT

Release Date Price: $7.41 (-1.72%)

Transcript

Alexandria Forbes

MeiraGTx Holdings plc - CEO, President & Director

Good morning. I'm Zandy Forbes, the President and CEO of MeiraGTx. Thank you for joining us today as we announce positive top line data from MGT009 Phase I/II clinical study, a botaretigene sparoparvovec for the treatment of patients suffering from X-linked retinitis pigmentosa with disease-causing variants in the eye-specific form of the RPGR gene.

Botaretigene sparoparvovec is an investigational gene therapy in development for the treatment of patients with X-linked retinitis pigmentosa, which was previously called AAV-RPGR. And for the ease of presentation today, I'm just going to call it botaretigene.

Before we begin, please note that we will be making forward-looking statements as part of this presentation, which statements are subject to certain risks and uncertainties that may cause actual results, performance or achievements to materially differ from those forecasted. Specificity of these risks are described in our press release and most recent filings with the SEC.

I'm joined this morning by

Already have an account? Log in

Get the full story

Start 7-Day Free Trial

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

30-Day 100% money back guarantee

You are not charged until the trial ends. Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Mobile App 中文

Education

Financial Glossary Tutorials FAQ Schedule Free Session Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us ETF Advertise Site Map Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.